Euro RSCG Life splits PR function, recruits Catlett

Share this article:
Euro RSCG Life has split its communications practice into product and corporate PR divisions, naming former Ketchum healthcare head David Catlett president of the product PR unit.

Catlett will serve as president of Euro RSCG Life PR, which will handle product PR for clients including Sanofi-Aventis, Galderma and Colgate-Palmolive's Hill's Pet Nutrition. Noonan Russo, formerly the firm's healthcare PR brand, will handle investor relations and other corporate PR functions, with a focus on biotechs, and continues to be led by Tony Russo.

After starting out in pharmaceuticals with Novartis predecessor Ciba-Geigy, Searle, Abbott and the Chicago Lung Association, Catlett spent 15 years at Ketchum, building its global healthcare practice and handling major brands like Lipitor. He and Russo report to Al Paz, CEO of Havas network's marketing services group.

Euro RSCG Life PR is “a little smaller and more focused” than Ketchum, Catlett said, adding that the network's exclusive focus on healthcare gives the firm a boutique feel. “There's also a lot of resources that can be brought to bear to service our clients.” Client brands include Sanofi-Aventis' Lantus and Lovenox and Galderma's Differin, Tri-Luma and MetroGel.

Catlett's successor has not yet been appointed, but Nancy Hicks has become associate director of the North American healthcare practice, a new position. Hicks was previously head of the firm's Washington practice. Ketchum's global healthcare practice reports to Lorraine Thelian, senior partner.

Share this article:
You must be a registered member of MMM to post a comment.

Next Article in Channel


Patient access to pharmaceuticals is a tale of two worlds—affordability has improved for the majority, while the minority is hampered by cost, distribution and red tape. To provide marketers with a well-rounded perspective, MM&M presents this e-book chock full of key insights. Click here to access it.

More in Channel

Five things for pharma marketers to know: Monday, September 15

Five things for pharma marketers to know: ...

Pharma has sought 76 meetings with FDA over biosimilars; Gilead licenses Sovaldi to India generic drugmakers; Pfizer and Ranbaxy Lipitor lawsuit dismissed.

Liraglutide, aiming for new indication, gets new name

Liraglutide, aiming for new indication, gets new name

Why Novo Nordisk is choosing not to leverage Victoza's brand equity as it seeks a weight-loss indication for liraglutide.

Five things for pharma marketers to know: Friday, September 12

Five things for pharma marketers to know: Friday, ...

An FDA panel voted in favor of liraglutide for weight loss; Allergan investors backing an attempted takeover of the firm crossed a critical threshold; and 100 million health wearables are ...